

Induction of Abortion (First Trimester)

References to July 2007

Review Articles

Medical methods of early abortion in developing countries. Consensus statement. The Population Council. *Contraception* 1998;**58**:257-9.

ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Medical management of abortion. *Obstet.Gynecol.* 2001;**97**:suppl-13.

[Anon]. Co-administration of mifepristone and vaginal misoprostol for medical abortion may be as effective as sequential administration. *Reproductive Health Matters* 2006;**14**:236-7.

Althaus F. As a medical abortion regimen, misoprostol alone is not highly effective, but rarely causes side effects. *Family Planning Perspectives* 1996;**28**:180-1.

Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. *Hum.Reprod.* 1998;**13**:2962-5.

Aubeny E.,Baulieu EE. Contragestion with Ru486 and An Orally Active Prostaglandin. *Comptes Rendus de l Academie des Sciences Serie Iii-Sciences de la Vie-Life Sciences* 1991;**312**:539-45.

Aubeny E. Methods of abortion in Europe during the first trimester of pregnancy. *Eur.J.Contracept.Reprod.Health Care* 1997;**2**:75-80.

Aubeny E. Evolution since 1989 in France of abortion by mifepristone (RU 486) associated with an analogue of prostaglandin. *Contraception Fertilité Sexualité* 1997;**25**:777-81.

Baird DT. Clinical use of mifepristone (RU 486). *Ann.Med.* 1993;**25**:65-9.

Baird DT. Medical abortion in Britain. *Br.J.Obstet.Gynaecol.* 1994;**101**:367-8.

Baird DT. Medical abortion in the first trimester. *Best.Pract.Res.Clin.Obstet.Gynaecol.* 2002;**16**:221-36.

Baulieu EE. The combined use of prostaglandin and antiprogestin in human fertility control. *Adv.Prostaglandin Thromboxane Leukot.Res.* 1995;**23**:55-62.

Beal MW.,Simmonds K. Clinical uses of mifepristone: an update for women's health practitioners. *J.Midwifery Womens Health* 2002;**47**:451-60.

Bechard dS. [Use of misoprostol in gynecology and obstetrics]. *Gynecol.Obstet.Fertil.* 2002;**30**:317-24.

Berer M. Medical abortion: Issues of choice and acceptability. *Reproductive Health Matters* 2005;**13**:25-34.

Berer M. Medical abortion: a fact sheet. *Reprod.Health Matters.* 2005;**13**:20-4.

Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy. A review of the evidence. *Contraception* 1999;**59**:209-17.

Blanchard K, Winikoff B, Coyaji K, Nguyen TN. Misoprostol alone--a new method of medical abortion? *J.Am.Med.Womens Assoc.* 2000;**55**:189-90.

Bygdeman M, Swahn ML, Gemzell-Danielsson K, Gottlieb C. The use of progesterone antagonists in combination with prostaglandin for termination of pregnancy. *Hum.Reprod.* 1994;**9 Suppl 1**:121-5.

Bygdeman M, Gemzell DK, Marions L, Swahn M. Pregnancy termination. *Steroids* 2000;**65**:801-5.

Bygdeman M, Danielsson KG. Options for early therapeutic abortion: a comparative review. *Drugs* 2002;**62**:2459-70.

Cheng L. Medical abortion in early pregnancy: experience in China. *Contraception* 2006;**74**:61-5.

Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. *N.Engl.J.Med.* 2000;**342**:946-56.

Christin-Maitre S, Bouchard P, Spitz IM. Drug therapy - Medical termination of pregnancy. *New England Journal of Medicine* 2000;**342**:946-56.

Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. *Contraception* 2007;**75**:245-50.

Coyaji K. Early medical abortion in India: three studies and their implications for abortion services. *J.Am.Med.Womens Assoc.* 2000;**55**:191-4.

Creinin MD, Edwards J. Early abortion: Surgical and medical options. *Current Problems in Obstetrics Gynecology and Fertility* 1997;**20**:6-32.

Creinin MD, Pymar HC. Medical abortion alternatives to mifepristone. *J.Am.Med.Womens Assoc.* 2000;**55**:127-32, 150.

Creinin MD. Medical abortion regimens: historical context and overview. *Am.J.Obstet.Gynecol.* 2000;**183**:S3-S9.

- Creinin MD. Current medical abortion care. *Curr.Womens Health Rep.* 2003;**3**:461-9.
- Daley J.,Grimes DA. A 26-year-old woman seeking an abortion - Discussion. *Jama-Journal of the American Medical Association* 1999;**282**:1169-75.
- De Costa CM. Early medical abortion in Australia: more common than statistics suggest? *Medical Journal of Australia* 2006;**185**:341.
- de Poncheville L, Marret H, Perrotin F, Lansac J, Body G. [Spontaneous abortions of first trimester pregnancy: is uterine aspiration still in line?]. *Gynecol.Obstet.Fertil.* 2002;**30**:799-806.
- DeHart RM,Morehead MS. Mifepristone. *Ann.Pharmacother.* 2001;**35**:707-19.
- Ferris LE, Basinski AS. Medical abortion: what does the research tell us? *CMAJ.* 1996;**154**:185-7.
- Foster AM, Wynn L, Rouhana A, Diaz-Olavarrieta C, Schaffer K, Trussell J. Providing medication abortion information to diverse communities: use patterns of a multilingual web site. *Contraception* 2006;**74**:264-71.
- Gallo MF, Cahill S, Castleman L, Mitchell EM. A systematic review of more than one dose of misoprostol after mifepristone for abortion up to 10 weeks of gestation. *Contraception* 2006;**74**:36-41.
- Ganatra B, Bygdeman M, Phan BT, Nguyen DV, Vu ML. From research to reality: the challenges of introducing medical abortion into service delivery in Vietnam. *Reprod.Health Matters.* 2004;**12**:105-13.
- Gold M, Luks D, Anderson MR. Medical options for early pregnancy termination. *Am.Fam.Physician* 1997;**56**:533-8.
- Goldberg AB, Greenberg MB, Darney PD. Drug therapy: Misoprostol and pregnancy. *New England Journal of Medicine* 2001;**344**:38-47.
- Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. *N.Engl.J.Med.* 2001;**344**:38-47.
- Goldberg JR, Plescia MG, Anastasio GD. Mifepristone (RU 486): current knowledge and future prospects. *Arch.Fam.Med.* 1998;**7**:219-22.
- Grimes DA. Mifepristone (RU 486) for induced abortion. *Womens Health Issues* 1993;**3**:171-5.
- Grimes DA. Medical abortion in early pregnancy: a review of the evidence. *Obstet.Gynecol.* 1997;**89**:790-6.

- Grimes DA, Creinin MD. Induced abortion: an overview for internists. *Ann.Intern.Med.* 2004;**140**:620-6.
- Grossman D, Ellertson C, Grimes DA, Walker D. Routine follow-up visits after first-trimester induced abortion. *Obstetrics and Gynecology* 2004;**103**:738-45.
- Guengant JP, Bangou J, Elul B, Ellertson C. Mifepristone-misoprostol medical abortion: home administration of misoprostol in Guadeloupe. *Contraception* 1999;**60**:167-72.
- Gupta S. Early non-surgical abortion - give women the choice. *Human Reproduction* 1998;**13**:2379-81.
- Hamoda H, Flett GM. Medical termination of pregnancy in the early first trimester. *J.Fam.Plann.Reprod.Health Care* 2005;**31**:10-4.
- Henshaw RC. Mifepristone (RU486) and abortion. *Med.J.Aust.* 1997;**167**:292-3.
- Ho PC, Yu Ng EH, Tang OS. Mifepristone: contraceptive and non-contraceptive uses. *Curr.Opin.Obstet.Gynecol.* 2002;**14**:325-30.
- Hollander D. Mifepristone and Vaginal Misoprostol Are Effective, Acceptable and Inexpensive Medical Abortion Regimen. *Family Planning Perspectives* 1995;**27**:223-4.
- Joffe C, Yanow S. Advanced practice clinicians as abortion providers: Current developments in the United States. *Reproductive Health Matters* 2004;**12**:198-206.
- Kahn JG, Becker BJ, MacIsaac L, Amory JK, Neuhaus J, Olkin I *et al.* The efficacy of medical abortion: a meta-analysis. *Contraception* 2000;**61**:29-40.
- Kulier R, Gulmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. *Cochrane.Database.Syst.Rev.* 2004;CD002855.
- Lokugamage AU, Refaey HE, Rodeck CH. Misoprostol and pregnancy: ever-increasing indications of effective usage. *Curr.Opin.Obstet.Gynecol.* 2003;**15**:513-8.
- Lourenco AP, Reuse C, de Ziegler D. [Early pregnancy termination: what the generalist should know]. *Rev.Med.Suisse* 2006;**2**:1340-5.
- Mackenzie SJ, Yeo S. Pregnancy interruption using mifepristone (RU-486). A new choice for women in the USA. *J.Nurse Midwifery* 1997;**42**:86-90.
- Mathai M. Preventing unsafe abortion in India. *Indian J.Med.Res.* 2005;**122**:98-9.
- Meckstroth KR, Darney PD. Prostaglandins for first-trimester termination. *Best.Pract.Res.Clin.Obstet.Gynaecol.* 2003;**17**:745-63.
- Moore ML. Misoprostol-is more research needed? *J.Perinat.Educ.* 2002;**11**:43-7.

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to mifepristone for early medical abortion. *Int.J.Gynaecol.Obstet.* 2007;**96**:212-8.

Murray S, Muse K. Mifepristone and first trimester abortion. *Clin.Obstet.Gynecol.* 1996;**39**:474-85.

Narrigan D. Early abortion - Update and implications for midwifery practice. *Journal of Nurse-Midwifery* 1998;**43**:492-501.

Narrigan D. Early abortion. Update and implications for midwifery practice. *J.Nurse Midwifery* 1998;**43**:492-501.

Newhall EP, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. *Am.J.Obstet.Gynecol.* 2000;**183**:S44-S53.

Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. *Lancet* 1991;**338**:1233-6.

Nothnagle M, Taylor JS. Medical methods for first-trimester abortion. *Am.Fam.Physician* 2004;**70**:81-3.

Paul M. Office management of early induced abortion. *Clin.Obstet.Gynecol.* 1999;**42**:290-305.

Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. *Am.J.Obstet.Gynecol.* 2000;**183**:S34-S43.

Peplow PV. RU486 combined with PGE1 analog in voluntary termination of early pregnancy--a comparison of recent findings with gemeprost or misoprostol. *Contraception* 1994;**50**:69-75.

Philip NM, Winikoff B, Moore K, Blumenthal P. A consensus regimen for early abortion with misoprostol. *Int.J.Gynaecol.Obstet.* 2004;**87**:281-3.

Pymar HC, Creinin MD. Alternatives to mifepristone regimens for medical abortion. *Am.J.Obstet.Gynecol.* 2000;**183**:S54-S64.

Say L, Kulier R, Gulmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. *Cochrane.Database.Syst.Rev.* 2002;CD003037.

Say L, Kulier R, Gulmezoglu M, Campana A. Medical versus surgical methods for first trimester termination of pregnancy. *Cochrane.Database.Syst.Rev.* 2005;CD003037.

Schaff EA, Eisinger SH, Stadalius LS. Weighing The Options In Medical Abortion. *Medscape.Womens Health* 1997;**2**:1.

- Schaff EA, Fielding SL. A comparison of the Abortion Rights Mobilization and Population Council trials. *J.Am.Med.Womens Assoc.* 2000;**55**:137-40.
- Scheepers HC, van Erp EJ, van den Bergh AS. Use of misoprostol in first and second trimester abortion: a review. *Obstet.Gynecol.Surv.* 1999;**54**:592-600.
- Schreiber C, Creinin M. Mifepristone in abortion care. *Seminars in Reproductive Medicine* 2005;**23**:82-91.
- Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. *Contraception* 2004;**70**:183-90.
- Shannon C, Brothers LP, Philip NM, Winikoff B. Ectopic pregnancy and medical abortion. *Obstetrics and Gynecology* 2004;**104**:161-7.
- Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. *Contraception* 2006;**74**:48-55.
- Song J. Use of misoprostol in obstetrics and gynecology. *Obstet.Gynecol.Surv.* 2000;**55**:503-10.
- Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. *Obstet.Gynecol.* 2004;**104**:174-85.
- Tang OS, Ho PC. The use of misoprostol for early pregnancy failure. *Curr.Opin.Obstet.Gynecol.* 2006;**18**:581-6.
- Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. *Contraception* 2006;**74**:26-30.
- Tang OS, Ho PC. Clinical applications of mifepristone. *Gynecological Endocrinology* 2006;**22**:655-9.
- Templeton A. Misoprostol for all? *Br.J.Obstet.Gynaecol.* 1998;**105**:937-9.
- Trupin SR, Moreno C. Medical abortion: overview and management. *Medscape.Womens Health* 2001;**6**:4.
- Trussell J, Ellertson C. Estimating the efficacy of medical abortion. *Contraception* 1999;**60**:119-35.
- Ulmann A, Silvestre L. RU486: the French experience. *Hum.Reprod.* 1994;**9 Suppl 1**:126-30.
- Van Look PFA, Cottingham JC. Unsafe abortion: an avoidable tragedy. *Best Practice & Research in Clinical Obstetrics & Gynaecology* 2002;**16**:205-20.
- von Hertzen H. Research on regimens for early medical abortion. *J.Am.Med.Womens Assoc.* 2000;**55**:133-6, 150.

von Hertzen H, Baird D. Frequently asked questions about medical abortion. *Contraception* 2006;**74**:3-10.

Westfall JM, O'Brien-Gonzales A, Barley G. Update on early medical and surgical abortion. *J.Womens Health* 1998;**7**:991-5.

Wu S. Medical abortion in China. *J.Am.Med.Womens Assoc.* 2000;**55**:197-9, 204.

Zust S, Hosli I, Surbek D, Holzgreve W. Side effects of Misoprostol therapy during pregnancy. *Zeitschrift fur Geburtshilfe und Neonatologie* 2001;**205**:43-8.

Zust S, Hosli I, Surbek D, Holzgreve W. [Adverse effects of misoprostol in pregnancy]. *Z.Geburtshilfe Neonatol.* 2001;**205**:43-8.

Clinical Studies

Randomised Controlled Trials

Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. *BJOG.* 2000;**107**:524-30.

[Anon]. Abortion with vaginal misoprostol alone - 88% effective. *Reproductive Health Matters* 2002;**10**:192.

Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. *Hum.Reprod.* 2004;**19**:81-4.

Arvidsson C, Hellborg M, Gemzell-Danielsson K. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2005;**123**:87-91.

Ashok PW, Kidd A, Flett GM, Fitzmaurice A, Graham W, Templeton A. A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. *Hum.Reprod.* 2002;**17**:92-8.

Ashok PW, Hamoda H, Flett GMM, Kidd A, Fitzmaurice A, Templeton A. Patient preference in a randomized study comparing medical and surgical abortion at 10-13 weeks gestation. *Contraception* 2005;**71**:143-8.

Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. *Eur.J.Contracept.Reprod.Health Care* 2000;**5**:171-6.

Baird DT, Sukcharoen N, Thong KJ. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. *Hum.Reprod.* 1995;**10**:1521-7.

Bartley J, Brown A, Elton R, Baird DT. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. *Hum.Reprod.* 2001;**16**:2098-102.

Bhattacharya M, Das SK, Gopalakrishnan K, Kodkany BS, Mukherjee GG, Mukherjee K *et al.* A multicentre randomized comparative clinical trial of 200 mg RU486 (mifepristone) single dose followed by either 5 mg 9-methylene PGE(2) gel (meteneprost) or 600 µg oral PGE(1) (misoprostol) for termination of early pregnancy within 28 days of missed menstrual period. *Contraception* 2000;**62**:125-30.

Blanchard K, Shochet T, Coyaji K, Thi Nhu NN, Winikoff B. Misoprostol alone for early abortion: an evaluation of seven potential regimens. *Contraception* 2005;**72**:91-7.

Blohm F, Friden BE, Milsom I, Platz-Christensen JJ, Nielsen S. A randomised double blind trial comparing misoprostol or placebo in the management of early miscarriage. *BJOG.* 2005;**112**:1090-5.

Bugalho A, Faundes A, Jamisse L, Usfa M, Maria E, Bique C. Evaluation of the effectiveness of vaginal misoprostol to induce first trimester abortion. *Contraception* 1996;**53**:244-6.

Burnett MA, Corbett CA, Gertenstein RJ. A randomized trial of laminaria tents versus vaginal misoprostol for cervical ripening in first trimester surgical abortion. *J.Obstet.Gynaecol.Can.* 2005;**27**:38-42.

Carbonell IEJ, Velazco A, Varela L, Cabezas E, Fernandez C, Sanchez C. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. A randomized trial. *Contraception* 1997;**56**:169-74.

Carbonell JL, Varela L, Velazco A, Cabezas E, Fernandez C, Sanchez C. Oral methotrexate and vaginal misoprostol for early abortion. *Contraception* 1998;**57**:83-8.

Chen AY, Mottl-Santiago J, Vragovic O, Wasserman S, Borgatta L. Bleeding after medication-induced termination of pregnancy with two dosing schedules of mifepristone and misoprostol. *Contraception* 2006;**73**:415-9.

Chen HJ, Lin YH, Hwang JL. Medical abortion in combination with laminaria for first-trimester termination of pregnancy. *Int.J.Gynaecol.Obstet.* 2004;**85**:279-80.

Cheng L. [Termination of 10-16 weeks's gestation with mifepristone plus misoprostol: a multicentre randomized clinical trial]. *Zhonghua Fu Chan Ke.Za Zhi.* 1999;**34**:268-71.

Coyaji K, Krishna U, Ambardekar S, Bracken H, Raote V, Mandlekar A *et al.* Are two doses of misoprostol after mifepristone for early abortion better than one? *BJOG*. 2007;**114**:271-8.

Creinin MD, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion. A randomized controlled trial. *JAMA* 1994;**272**:1190-5.

Creinin MD, Vittinghoff E, Galbraith S, Klaisle C. A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion. *Am.J.Obstet.Gynecol.* 1995;**173**:1578-84.

Creinin MD. Oral methotrexate and vaginal misoprostol for early abortion. *Contraception* 1996;**54**:15-8.

Creinin MD, Krohn MA. Methotrexate pharmacokinetics and effects in women receiving methotrexate 50 mg and 60 mg per square meter for early abortion. *Am.J.Obstet.Gynecol.* 1997;**177**:1444-9.

Creinin MD, Stewart-Akers AM, DeLoia JA. Methotrexate effects on trophoblast and the corpus luteum in early pregnancy. *Am.J.Obstet.Gynecol.* 1998;**179**:604-9.

Creinin MD, Carbonell JL, Schwartz JL, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. *Contraception* 1999;**59**:11-6.

Creinin MD. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. *Contraception* 2000;**62**:117-24.

Creinin MD, Pymar HC, Schwartz JL. Mifepristone 100 mg in abortion regimens. *Obstet.Gynecol.* 2001;**98**:434-9.

Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. *BJOG*. 2001;**108**:469-73.

Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. *Obstet.Gynecol.* 2004;**103**:851-9.

Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. *Obstet.Gynecol.* 2007;**109**:885-94.

El Refaey H, Templeton A. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure. *Br.J.Obstet.Gynaecol.* 1994;**101**:792-6.

El Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. *N.Engl.J.Med.* 1995;**332**:983-7.

Esteve JLC, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg or 50 mg of oral methotrexate followed by vaginal misoprostol 7 days after for early abortion - A randomized trial. *Gynecologic and Obstetric Investigation* 1999;**47**:182-7.

Fiala C, Aronsson A, Stephansson O, Gemzell-Danielsson K. Effects of slow release misoprostol on uterine contractility in early pregnancy. *Hum.Reprod.* 2005;**20**:2648-52.

Guest J, Chien P, Thomson M, Kosseim ML. Randomised controlled trial comparing efficacy of same day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36- to 48-hour protocol. *BJOG.* 2005;**112**:1457.

Guest J, Chien PF, Thomson MA, Kosseim ML. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. *BJOG.* 2007;**114**:207-15.

Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. *BJOG.* 2005;**112**:1102-8.

Henry AM, Haukkamaa M. Comparison of vaginal misoprostol and gemeprost as pre-treatment in first trimester pregnancy interruption. *Br.J.Obstet.Gynaecol.* 1999;**106**:540-3.

Honkanen H, Piaggio G, Herten H, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K *et al.* WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. *BJOG.* 2004;**111**:715-25.

Huang L, Shi Y, Chen X. [The immunohistochemical studies on estradiol and progesterone receptors in human decidua after terminating early pregnancy by mifepristone]. *Zhonghua Fu Chan Ke.Za Zhi.* 1999;**34**:275-7.

Jain JK, Mishell DR. Comparison of Intravaginal Misoprostol with Prostaglandin-E(2) for Termination of 2Nd-Trimester Pregnancy. *New England Journal of Medicine* 1994;**331**:290-3.

Jain JK, Meckstroth KR, Park M, Mishell DR, Jr. A comparison of tamoxifen and misoprostol to misoprostol alone for early pregnancy termination. *Contraception* 1999;**60**:353-6.

Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR, Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. *Hum.Reprod.* 2002;**17**:1477-82.

- Jing X., Weng L. [A study on the optimal regimen of mifepristone with prostaglandin for termination of early pregnancy]. *Zhonghua Fu Chan Ke.Za Zhi*. 1995;**30**:38-41.
- Khazardoost S, Hantoushzadeh S, Madani MM. A randomised trial of two regimens of vaginal misoprostol to manage termination of pregnancy of up to 16 weeks. *Aust.N.Z.J.Obstet.Gynaecol*. 2007;**47**:226-9.
- Kovavisarach E., Jamnansiri C. Intravaginal misoprostol 600 microg and 800 microg for the treatment of early pregnancy failure. *Int.J.Gynaecol.Obstet*. 2005;**90**:208-12.
- Lader L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial (vol 284, pg 1948, 2000). *Jama-Journal of the American Medical Association* 2000;**284**:2597.
- Liao AH, Han XJ, Wu SY, Xiao DZ, Xiong CL, Wu XR. Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion. *Eur.J.Obstet.Gynecol.Reprod.Biol*. 2004;**116**:211-6.
- Martin CW, Brown AH, Baird DT. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. *Contraception* 1998;**58**:99-103.
- McKinley C, Thong KJ, Baird DT. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. *Hum.Reprod*. 1993;**8**:1502-5.
- Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: Drug absorption and uterine response. *Obstet.Gynecol*. 2006;**108**:582-90.
- Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E *et al*. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. *Contraception* 2005;**72**:328-32.
- Mittal S, Agarwal S, Kumar S, Batra A. Comparison of oral versus vaginal misoprostol & continued use of misoprostol after mifepristone for early medical abortion. *Indian J.Med.Res*. 2005;**122**:132-6.
- Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. *Hum.Reprod*. 2000;**15**:1159-62.
- Okman-Kilic T., Kucuk M. Rectal misoprostol vs vaginal misoprostol for first trimester termination of pregnancy. *Int.J.Gynaecol.Obstet*. 2004;**85**:64-5.
- Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and misoprostol used alone or in combination for early abortion. *Contraception* 1999;**59**:389-94.

- Rabe T, Basse H, Thuro H, Kiesel L, Runnebaum B. [Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester]. *Geburtshilfe Frauenheilkd.* 1987;**47**:324-31.
- Richardson CR. Can vaginal misoprostol be administered 1 to 3 days after mifepristone without loss of efficacy or an increase in adverse events? *J.Fam.Pract.* 2001;**50**:9.
- Ruangchainikhom W, Phongphissanou E, Bhekasuta J, Sarapak S. Effectiveness of 400 or 600 micrograms of vaginal misoprostol for terminations of early pregnancies. *J.Med.Assoc.Thai.* 2006;**89**:928-33.
- Sang GW, Weng LJ, Shao QX, Du MK, Wu XZ, Lu YL *et al.* Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China. *Contraception* 1994;**50**:501-10.
- Sang GW, Weng LJ, Shao QX. [Termination of early pregnancy by two regimens of mifepristone with misoprostol: a multicentre clinical trial]. *Zhonghua Fu Chan Ke.Za Zhi.* 1994;**29**:735-8, 763.
- Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS *et al.* Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. *JAMA* 2000;**284**:1948-53.
- Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. *Contraception* 2001;**64**:81-5.
- Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. *Contraception* 2002;**66**:247-50.
- Schaub B, Fuhrer P, Sainte-Rose D. [Intravaginal misoprostol before induced abortion in nulliparous women]. *Contracept.Fertil.Sex* 1996;**24**:67-71.
- Schaub B, Fuhrer P, SainteRose D. Intravaginal misoprostol before first trimester induced abortion in nulliparous women. *Contraception Fertilite Sexualite* 1996;**24**:67-71.
- Shannon C, Wiebe E, Jacot F, Guilbert E, Dunn S, Sheldon WR *et al.* Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. *BJOG.* 2006;**113**:621-8.
- Stojnic J, Ljubic A, Jeremic K, Radunovic N, Tulic I, Boskovic V *et al.* [Medicamentous abortion with mifepristone and misoprostol in Serbia and Montenegro]. *Vojnosanit.Pregl.* 2006;**63**:558-63.

Takkar D, Agarwal N, Sehgal R, Buckshee K. Early abortion by mifepristone (RU 486) followed by vaginal gel (meteneprost) versus oral (misoprostol) prostaglandin. *Adv.Contracept.* 1999;**15**:163-73.

Tang OS, Gao PP, Cheng L, Lee SW, Ho PC. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. *Hum.Reprod.* 1999;**14**:722-5.

Tang OS, Lee SW, Ho PC. A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. *Hum.Reprod.* 2002;**17**:2865-8.

Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. *Hum.Reprod.* 2003;**18**:2315-8.

Teal SB, Dempsey-Fanning A, Westhoff C. Predictors of acceptability of medication abortion. *Contraception* 2007;**75**:224-9.

Vimala N, Mittal S, Kumar S. Sublingual misoprostol before first trimester abortion: a comparative study using two dose regimens. *Indian J.Med.Sci.* 2004;**58**:54-61.

von Hertzen H, Honkanen H, Piaggio G, Bartfai G, Erdenetungalag R, Gemzell-Danielsson K *et al.* WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. *BJOG.* 2003;**110**:808-18.

von Hertzen H, Piaggio G, Huong NT, Arustamyan K, Cabezas E, Gomez M *et al.* Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. *Lancet* 2007;**369**:1938-46.

Wang Z. [Prevent from bleeding after medical abortion through prolonged application of mifepristone with misoprostol for terminating early pregnancy]. *Zhonghua Fu Chan Ke.Za Zhi.* 2000;**35**:554-7.

Westhoffa C, Dasmahapatra R, Schaff E. Analgesia during at-home use of misoprostol as part of a medical abortion regimen. *Contraception* 2000;**62**:311-4.

Wiebe E, Dunn S, Guilbert E, Jacot F, Lugtig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. *Obstet.Gynecol.* 2002;**99**:813-9.

Wiebe ER, Rawling MJ. Vaginal misoprostol before first trimester abortion. *Int.J.Gynaecol.Obstet.* 1998;**60**:175-6.

Wiebe ER. Tamoxifen compared to methotrexate when used with misoprostol for abortion. *Contraception* 1999;**59**:265-70.

Wiebe ER, Trouton K. Comparing vaginal and buccal misoprostol when used after methotrexate for early abortion. *Contraception* 2004;**70**:463-6.

Wiebe ER, Trouton KJ, Lima R. Misoprostol alone vs. methotrexate followed by misoprostol for early abortion. *Int.J.Gynaecol.Obstet.* 2006;**95**:286-7.

Observational Studies

[Luteal phase treatment with mifepristone and misoprostol for prevention of pregnancy]. *Zhonghua Fu Chan Ke.Za Zhi.* 2003;**38**:563-6.

Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. *Bjog-An International Journal of Obstetrics and Gynaecology* 2007;**114**:561-2.

[Anon]. Acceptability and side effects of early abortion with mifepristone-misoprostol compared to vacuum aspiration in China, Cuba and India. *Reproductive Health Matters* 2000;**8**:185.

[Anon]. Complete, early abortion with misoprostol. *Reproductive Health Matters* 2001;**9**:190.

[Anon]. Abortion with sublingual misoprostol alone - 86% effective. *Reproductive Health Matters* 2002;**10**:192.

[Anon]. Sublingual and vaginal misoprostol are equally effective in early medical abortion. *Reproductive Health Matters* 2004;**12**:226.

[Anon]. Misoprostol alone for medical abortion in the US. *Reproductive Health Matters* 2005;**13**:210-1.

[Anon]. Shortening the interval between mifepristone and misoprostol: preliminary findings. *Reproductive Health Matters* 2005;**13**:166.

Acharya G, Haugen M, Brathen A, Nilsen I, Maltau JM. Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting. *Acta Obstet.Gynecol.Scand.* 2004;**83**:390-4.

Akin A, Kocoglu GO, Akin L. Study supports the introduction of early medical abortion in Turkey. *Reprod.Health Matters.* 2005;**13**:101-9.

Aldrich T, Winikoff B. Does methotrexate confer a significant advantage over misoprostol alone for early medical abortion? A retrospective analysis of 8678 abortions. *BJOG.* 2007;**114**:555-62.

- Allen RH, Westhoff C, De Nonno L, Fielding SL, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing, and indications. *Obstet.Gynecol.* 2001;**98**:101-6.
- Anjum ZK. Termination of early pregnancy with a reduced oral dose of mifepristone and vaginal misoprostol. *S.Afr.Med.J.* 2000;**90**:889-91.
- Ashima T, Vinita A, Shalini R. Early medical abortion: a new regimen up to 49 days' gestation. *Aust.N.Z.J.Obstet.Gynaecol.* 2005;**45**:137-9.
- Ashok PW, Flett GM, Templeton A. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol. *Lancet* 1998;**352**:542-3.
- Aubeny E, Peyron R, Turpin CL, Renault M, Targosz V, Silvestre L *et al.* Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. *Int.J.Fertil.Menopausal Stud.* 1995;**40 Suppl 2**:85-91.
- Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, Whitehead S *et al.* Risk factors for legal induced abortion-related mortality in the United States. *Obstetrics and Gynecology* 2004;**103**:729-37.
- Bartley J, Tong S, Everington D, Baird DT. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. *Contraception* 2000;**62**:297-303.
- Basu R, Gundlach T, Tasker M. Mifepristone and misoprostol for medical termination of pregnancy: the effectiveness of a flexible regimen. *J.Fam.Plann.Reprod.Health Care* 2003;**29**:139-41.
- Benson J, Clark KA, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: a provider survey. *Contraception* 2003;**67**:287-94.
- Bentov Y, Sheiner E, Katz M. Misoprostol overdose during the first trimester of pregnancy. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2004;**115**:108-9.
- Billings DL. Misoprostol alone for early medical abortion in a Latin American clinic setting. *Reprod.Health Matters.* 2004;**12**:57-64.
- Bjorge L, Johnsen SL, Midboe G, Augestad G, Okland I, Helland H *et al.* Early pregnancy termination with mifepristone and misoprostol in Norway. *Acta Obstet.Gynecol.Scand.* 2001;**80**:1056-61.
- Blanch G, Quenby S, Ballantyne ES, Gosden CM, Neilson JP, Holland K. Embryonic abnormalities at medical termination of pregnancy with mifepristone and misoprostol during first trimester: observational study. *BMJ* 1998;**316**:1712-3.

Borgatta L, Burnhill M, Haskell S, Nichols M, Leonhardt K. Instituting medical abortion services: changes in outcome and acceptability related to provider experience. *J.Am.Med.Womens Assoc.* 2000;**55**:173-6.

Borgatta L, French A, Vragovic O, Burnhill M. Early medical abortion with methotrexate. Outcome and satisfaction among women aged 15-20 years. *J.Pediatr.Adolesc.Gynecol.* 2000;**13**:87-8.

Borgatta L, Burnhill MS, Tyson J, Leonhardt KK, Hausknecht RU, Haskell S. Early medical abortion with methotrexate and misoprostol. *Obstet.Gynecol.* 2001;**97**:11-6.

Borgatta L, French A, Vragovic O, Burnhill MS. Early medical abortion with methotrexate and misoprostol: outcomes and satisfaction among women aged 15-21 years. *J.Pediatr.Adolesc.Gynecol.* 2001;**14**:9-16.

Borgatta L, Mullally B, Vragovic O, Gittinger E, Chen A. Misoprostol as the primary agent for medical abortion in a low-income urban setting. *Contraception* 2004;**70**:121-6.

Bracken H, Gliozheni O, Kati K, Manoku N, Moisiu R, Shannon C *et al.* Mifepristone medical abortion in Albania: results from a pilot clinical research study. *Eur.J.Contracept.Reprod.Health Care* 2006;**11**:38-46.

Bugalho A, Bique C, Almeida L, Bergstrom S. Pregnancy interruption by vaginal misoprostol. *Gynecol.Obstet.Invest* 1993;**36**:226-9.

Bugalho A, Mocumbi S, Faundes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 microg of vaginal misoprostol. *Contraception* 2000;**61**:47-50.

Cabezas E. Medical versus surgical abortion. *Int.J.Gynaecol.Obstet.* 1998;**63 Suppl 1**:S141-S146.

Cameron ST, Glasier AF, Logan J, Benton L, Baird DT. Impact of the introduction of new medical methods on therapeutic abortions at the Royal Infirmary of Edinburgh. *Br.J.Obstet.Gynaecol.* 1996;**103**:1222-9.

Carbonell Esteve JL, Varela L, Velazco A, Cabezas E, Tanda R, Sanchez C. Vaginal misoprostol for late first trimester abortion. *Contraception* 1998;**57**:329-33.

Carbonell JL, Varela L, Velazco A, Fernandez C, Sanchez C. The use of misoprostol for abortion at < or = 9 weeks' gestation. *Eur.J.Contracept.Reprod.Health Care* 1997;**2**:181-5.

Carbonell JL, Varela L, Velazco A, Fernandez C. The use of misoprostol for termination of early pregnancy. *Contraception* 1997;**55**:165-8.

Carbonell JL, Varela L, Velazco A, Tanda R, Sanchez C. Vaginal misoprostol for abortion at 10-13 weeks' gestation. *Eur.J.Contracept.Reprod.Health Care* 1999;**4**:35-40.

Carbonell JL, Varela L, Velazco A, Tanda R, Barambio S, Chami S. Vaginal misoprostol 600 microg for early abortion. *Eur.J.Contracept.Reprod.Health Care* 2000;**5**:46-51.

Carbonell JL, Rodriguez J, Aragon S, Velazco A, Tanda R, Sanchez C *et al.* Vaginal misoprostol 1000 microg for early abortion. *Contraception* 2001;**63**:131-6.

Carbonell JL, Rodriguez J, Velazco A, Tanda R, Sanchez C, Barambio S *et al.* Oral and vaginal misoprostol 800 microg every 8 h for early abortion. *Contraception* 2003;**67**:457-62.

Chanprapaph P, Tongsong T, Wongtra-ngan S. Sonographic diagnosis of exencephaly: omphalocele at 11 weeks of gestation. *J.Obstet.Gynaecol.Res.* 2000;**26**:363-6.

Chao A, Chao AS, Wang ST, Wang TH. Mifepristone-induced abortion in one horn and a growing fetus in another horn in a patient with a twin pregnancy in a bicornuate uterus. *Fertil.Steril.* 2006;**86**:1764-5.

Cheung W, Tang OS, Lee SW, Ho PC. Pilot study on the use of sublingual misoprostol in termination of pregnancy up to 7 weeks gestation. *Contraception* 2003;**68**:97-9.

Child TJ, Thomas J, Rees M, MacKenzie IZ. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. *Hum.Reprod.* 2001;**16**:67-71.

Chou SY, Chen CY, Chiang HK, Chow PK, Wang CC, Hsu CS. Monitoring medical abortion using mifepristone/misoprostol combination with ultrasonogram and serum human chorionic gonadotropin. *Taiwan.J.Obstet.Gynecol.* 2006;**45**:48-52.

Choudhary N, Saha SC, Gopalan S. Abortion procedures in a tertiary care institution in India. *Int.J.Gynaecol.Obstet.* 2005;**91**:81-6.

Clark S, Blum J, Blanchard K, Galvao L, Fletcher H, Winikoff B. Misoprostol use in obstetrics and gynecology in Brazil, Jamaica, and the United States. *Int.J.Gynaecol.Obstet.* 2002;**76**:65-74.

Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. *Eur.J.Contracept.Reprod.Health Care* 2005;**10**:184-91.

Coelho HL, Teixeira AC, Cruz MD, Gonzaga SL, Arrais PS, Luchini L *et al.* Misoprostol - the Experience of Women in Fortaleza, Brazil. *Contraception* 1994;**49**:101-10.

- Coelho HL, Teixeira AC, Cruz MF, Gonzaga SL, Arrais PS, Luchini L *et al.* Misoprostol: the experience of women in Fortaleza, Brazil. *Contraception* 1994;**49**:101-10.
- Coelho KE, Sarmiento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV *et al.* Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogyrosis. *Am.J.Med.Genet.* 2000;**95**:297-301.
- Coles MS, Koenigs LP. Self-induced medical abortion in an adolescent. *J.Pediatr.Adolesc.Gynecol.* 2007;**20**:93-5.
- Costa SH, Vessey MP. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. *Lancet* 1993;**341**:1258-61.
- Coyaji K, Elul B, Krishna U, Otiv S, Ambardekar S, Bopardikar A *et al.* Mifepristone-misoprostol abortion: a trial in rural and urban Maharashtra, India. *Contraception* 2002;**66**:33-40.
- Creinin MD, Darney PD. Methotrexate and misoprostol for early abortion. *Contraception* 1993;**48**:339-48.
- Creinin MD. Methotrexate and misoprostol for abortion at 57-63 days gestation. *Contraception* 1994;**50**:511-5.
- Creinin MD, Park M. Acceptability of medical abortion with methotrexate and misoprostol. *Contraception* 1995;**52**:41-4.
- Creinin MD. Medically induced abortion in a woman with a large myomatous uterus. *Am.J.Obstet.Gynecol.* 1996;**175**:1379-80.
- Creinin MD, Burke AE. Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability. *Contraception* 1996;**54**:19-22.
- Creinin MD, Vittinghoff E, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. *Contraception* 1996;**53**:321-7.
- Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. *Am.J.Obstet.Gynecol.* 1996;**174**:776-8.
- Creinin MD. Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol. *Contraception* 1997;**56**:367-71.
- Creinin MD, Vittinghoff E, Schaff E, Klaisle C, Darney PD, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. *Obstet.Gynecol.* 1997;**90**:611-6.

Creinin MD, Spitz IM. Use of various ultrasonographic criteria to evaluate the efficacy of mifepristone and misoprostol for medical abortion. *Am.J.Obstet.Gynecol.* 1999;**181**:1419-24.

Creinin MD, Wiebe E, Gold M. Methotrexate and misoprostol for early abortion in adolescent women. *J.Pediatr.Adolesc.Gynecol.* 1999;**12**:71-7.

Creinin MD. Conception rates after abortion with methotrexate and misoprostol. *Int.J.Gynaecol.Obstet.* 1999;**65**:183-8.

Creinin MD, Potter C, Holovanisin M, Janczukiewicz L, Pymar HC, Schwartz JL *et al.* Mifepristone and misoprostol and methotrexate/misoprostol in clinical practice for abortion. *Am.J.Obstet.Gynecol.* 2003;**188**:664-9.

Daley J, Grimes DA. A 26-year-old woman seeking an abortion - Discussion. *Jama-Journal of the American Medical Association* 1999;**282**:1169-75.

Danielsson KG, Marions L, Rodriguez A, Spur BW, Wong PY, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. *Obstet.Gynecol.* 1999;**93**:275-80.

Davis A, Westhoff C, De Nonno L. Bleeding patterns after early abortion with mifepristone and misoprostol or manual vacuum aspiration. *J.Am.Med.Womens Assoc.* 2000;**55**:141-4.

De Nonno LJ, Westhoff C, Fielding S, Schaff E. Timing of pain and bleeding after mifepristone-induced abortion. *Contraception* 2000;**62**:305-9.

DeLoia JA, Stewart-Akers AM, Creinin MD. Effects of methotrexate on trophoblast proliferation and local immune responses. *Hum.Reprod.* 1998;**13**:1063-9.

El Refaey H, Templeton A. Early induction of abortion by a combination of oral mifepristone and misoprostol administered by the vaginal route. *Contraception* 1994;**49**:111-4.

Elul B, Hajri S, Ngoc NN, Ellertson C, Slama CB, Pearlman E *et al.* Can women in less-developed countries use a simplified medical abortion regimen? *Lancet* 2001;**357**:1402-5.

Esteve JL, Varela L, Velazco A, Tanda R, Cabezas E, Sanchez C. Early abortion with 800 micrograms of misoprostol by the vaginal route. *Contraception* 1999;**59**:219-25.

Faucher P, Baunot N, Madelenat P. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. *Gynecol.Obstet.Fertil.* 2005;**33**:220-7.

- Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2003;**109**:190-5.
- Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K. Acceptability of home-use of misoprostol in medical abortion. *Contraception* 2004;**70**:387-92.
- Fielding SL, Schaff EA, Nam NY. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. *Contraception* 2002;**66**:27-31.
- Fielding SL, Schaff EA. Social context and the experience of a sample of US women taking RU-486 (mifepristone) for early abortion. *Qualitative Health Research* 2004;**14**:612-27.
- Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. *Clin.Dysmorphol.* 1993;**2**:76-80.
- Fox MC, Creinin MD, Harwood B. Mifepristone and vaginal misoprostol on the same day for abortion from 50 to 63 days' gestation. *Contraception* 2002;**66**:225-9.
- Gao P, Wang P. Clinical observation on termination of early pregnancy of 213 cases after caesarian section with repeated use of mifepristone and misoprostol. *Reprod.Contracept.* 1999;**10**:227-33.
- Gao PP, Lu YL, Gao XH, Ying YP. Clinical study on the termination of 388 high-risk early pregnancies with mifepristone and misoprostol. *Reprod.Contracept.* 1998;**9**:19-26.
- Garbin O, Vayssiere C, Bettahar-Lebugle K, Nisand I. Consistency of medical abortion efficacy from 5 through 14 weeks' gestation. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2006;**129**:36-40.
- Gautam R, Agrawal V. Early medical termination pregnancy with methotrexate and misoprostol in lower segment cesarean section cases. *J.Obstet.Gynaecol.Res.* 2003;**29**:251-6.
- Godfrey EM, Anderson A, Fielding SL, Meyn L, Creinin MD. Clinical utility of urine pregnancy assays to determine medical abortion outcome is limited. *Contraception* 2007;**75**:378-82.
- Goffman D, Cole DS, Bobby P, Garry DJ. Failed methotrexate termination of pregnancy: a case report. *J.Perinatol.* 2006;**26**:645-7.
- Goodyear-Smith F, Knowles A, Masters J. First trimester medical termination of pregnancy: an alternative for New Zealand women. *Aust.N.Z.J.Obstet.Gynaecol.* 2006;**46**:193-8.

- Graziosi GC, Bruinse HW, Reuwer PJ, Mol BW. Women's preferences for misoprostol in case of early pregnancy failure. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2006;**124**:184-6.
- Hajri S. Medical abortion: the Tunisian experience. *Afr.J.Reprod.Health* 2004;**8**:63-9.
- Hamoda H, Ashok PW, Dow J, Flett GM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. *Contraception* 2003;**68**:335-8.
- Hamoda H, Ashok PW, Flett GM, Templeton A. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. *BJOG.* 2004;**111**:996-1000.
- Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. *Contraception* 2005;**71**:327-32.
- Hamoda H, Critchley HO, Paterson K, Guthrie K, Rodger M, Penney GC. The acceptability of home medical abortion to women in UK settings. *BJOG.* 2005;**112**:781-5.
- Harper C, Winikoff B, Ellertson C, Coyaji K. Blood loss with mifepristone--misoprostol abortion: measures from a trial in China, Cuba and India. *Int.J.Gynaecol.Obstet.* 1998;**63**:39-49.
- Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? *Contraception* 2002;**65**:133-42.
- Hausknecht R. Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States. *Contraception* 2003;**67**:463-5.
- Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. *N.Engl.J.Med.* 1995;**333**:537-40.
- Heikinheimo O, Raivio T, Honkanen H, Ranta S, Janne OA. Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivity. *J.Clin.Endocrinol.Metab* 2003;**88**:323-6.
- Hollander D. Methotrexate with vaginal misoprostol is a safe, highly effective regimen for early medical abortion. *Family Planning Perspectives* 1997;**29**:45-6.
- Honkanen H, von Hertzen H. Users' perspectives on medical abortion in Finland. *Contraception* 2002;**65**:419-23.
- Honkanen H, Ranta S, Ylikorkala O, Heikinheimo O. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. *Hum.Reprod.* 2002;**17**:2315-9.

Honkanen H, Rutanen EM, Heikinheimo O. Differential kinetics of serum and cervical insulin-like growth factor-binding protein-1 during mifepristone-misoprostol-induced medical termination of early pregnancy. *Mol.Hum.Reprod.* 2004;**10**:65-70.

Honkanen H, Ranta S, Ylikorkala O, Heikinheimo O. Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy. *Acta Obstet.Gynecol.Scand.* 2005;**84**:134-9.

Iamakov K, Pekhlivanov B, Amaliev I. [Medical abortion using methotrexate and misoprostol. Efficacy and tolerability]. *Akush.Ginekol.(Sofia)* 2005;**44**:16-8.

Iversen OE, Midboe G, Johnsen SL, Augestad G, Okland I, Helland H *et al.* [Medical abortion--the first Norwegian experiences]. *Tidsskr.Nor Laegeforen.* 2003;**123**:2422-4.

Jain JK, Meckstroth KR, Mishell DR, Jr. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. *Am.J.Obstet.Gynecol.* 1999;**181**:1386-91.

Jain JK, Harwood B, Meckstroth KR, Mishell DR. Early pregnancy termination with vaginal misoprostol combined with loperamide and acetaminophen prophylaxis. *Contraception* 2001;**63**:217-21.

Jensen JT, Astley SJ, Morgan E, Nichols MD. Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study. *Contraception* 1999;**59**:153-9.

Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. *Am.J.Obstet.Gynecol.* 2000;**182**:1292-9.

Jerbi M, Hidar S, Sahraoui W, Essaidi H, Fekih M, Bibi M *et al.* [Mifepristone 100 mg for early medical abortion]. *J.Gynecol.Obstet.Biol.Reprod.(Paris)* 2005;**34**:257-61.

Jones MM, Fraser K. Misoprostol and attempted self-induction of abortion. *J.R.Soc.Med.* 1998;**91**:204-5.

Jwarah E, Greenhalf JO. Rupture of the uterus after 800 micrograms misoprostol given vaginally for termination of pregnancy. *BJOG.* 2000;**107**:807.

Kan AS, Ng EH, Ho PC. The role and comparison of two techniques of paracervical block for pain relief during suction evacuation for first-trimester pregnancy termination. *Contraception* 2004;**70**:159-63.

Kapp N, Borgatta L, Ellis SC, Stubblefield P. Simultaneous very low dose mifepristone and vaginal misoprostol for medical abortion. *Contraception* 2006;**73**:525-7.

- Khomasuridze AG, Tsertsvadze GL, Parculi MG, Parunashvili NR, Sulamanidze S. [Antiprogestosterone for medical abortion]. *Georgian.Med.News* 2006;24-8.
- Kim JO, Han JY, Choi JS, Ahn HK, Yang JH, Kang IS *et al.* Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report. *Reprod.Toxicol.* 2005;20:575-7.
- Kiran U, Amin P, Penketh RJ. Self-administration of vaginal misoprostol after mifepristone for termination of pregnancy: patient acceptability. *J.Obstet.Gynaecol.* 2006;26:679-81.
- Knudsen UB. First trimester abortion with mifepristone and vaginal misoprostol. *Contraception* 2001;63:247-50.
- Koopersmith TB, Mishell DR, Jr. The use of misoprostol for termination of early pregnancy. *Contraception* 1996;53:238-42.
- Lahiri S, Anobile CJ, Stewart P, Ledger WL. Changes in circulating concentrations of inhibins A and pro-alpha C during first trimester medical termination of pregnancy. *Hum.Reprod.* 2003;18:744-8.
- Largeaud M, El Guindi W, Perotti F, Montoya Y, Carles G, Seve B. [Medical termination of pregnancy at 9-14 weeks gestation. Prospective study of 105 cases in Saint-Laurent-du-Maroni (French Guyana)]. *J.Gynecol.Obstet.Biol.Reprod.(Paris)* 2004;33:119-24.
- Larkin M. Mifepristone-misoprostol effectively terminates pregnancy, reports US trial. *Lancet* 1998;351:1409.
- Li R, Wang Z, Wu R. The expression of integrin Beta 3 and intercellular adhesion molecule (ICAM-1) in decidua and chorionic villi during mifepristone induced abortion. *Reprod.Contracept.* 1999;10:214-9.
- Li YT, Chen FM, Chen TH, Li SC, Chen ML, Kuo TC. Concurrent use of mifepristone and misoprostol for early medical abortion. *Taiwan.J.Obstet.Gynecol.* 2006;45:325-8.
- Li YT, Chen TH, Kuo TC. Vaginal misoprostol for salvage therapy after failed medical abortion. *Int.J.Gynaecol.Obstet.* 2007;96:52-3.
- Lichtenberg ES. Gestational trophoblastic tumor after medical abortion. *Obstet.Gynecol.* 2003;101:1137-9.
- Lin M, Li YT, Chen FM, Wu SF, Tsai CW, Chen TH *et al.* Use of mifepristone and sublingual misoprostol for early medical abortion. *Taiwan.J.Obstet.Gynecol.* 2006;45:321-4.

Markovitch O, Tepper R, Klein Z, Fishman A, Aviram R. Sonographic appearance of the uterine cavity following administration of mifepristone and misoprostol for termination of pregnancy. *J.Clin.Ultrasound* 2006;**34**:278-82.

Marques-Dias MJ, Gonzalez CH, Rosemberg S. Mobius sequence in children exposed in utero to misoprostol: neuropathological study of three cases. *Birth Defects Res.A Clin.Mol.Teratol.* 2003;**67**:1002-7.

Mishell DR, Jr., Jain JK, Byrne JD, Lacarra MD. A medical method of early pregnancy termination using tamoxifen and misoprostol. *Contraception* 1998;**58**:1-6.

Mittal S. Contraception after medical abortion. *Contraception* 2006;**74**:56-60.

Mundle S, Elul B, Anand A, Kalyanwala S, Ughade S. Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center. *Contraception* 2007;**76**:66-70.

Murray S.,Wooltorton E. Septic shock after medical abortions with mifepristone (Mifeprex, RU 486) and misoprostol. *CMAJ.* 2005;**173**:485.

Murthy AS, Creinin MD, Harwood B, Schreiber C. A pilot study of mifepristone and misoprostol administered at the same time for abortion up to 49 days gestation. *Contraception* 2005;**71**:333-6.

Naz S.,Sultana N. Role of misoprostol for therapeutic termination of pregnancy from 10 -28 weeks of gestation. *J.Pak.Med.Assoc.* 2007;**57**:129-32.

Ngoc NT, Nhan VQ, Blum J, Mai TT, Durocher JM, Winikoff B. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. *BJOG.* 2004;**111**:814-9.

Niinimaki M, Martikainen H, Talvensaari-Mattila A. Increased risk for medical abortion failure for multiparous women. *Int.J.Gynaecol.Obstet.* 2004;**87**:174-5.

Ojidu JI.,Sabharwal SD. Setting up a one-stop mifepristone-misoprostol medical termination of pregnancy service for all gestations from 5 to 23 weeks--a review of 482 cases. *J.Obstet.Gynaecol.* 2001;**21**:386-8.

Ozeren S, Corakci A, Yucesoy I, Mercan R, Arslan A, Erhan G. Efficacy of methotrexate and misoprostol for early abortion. *Gynecol.Obstet.Invest* 1997;**44**:112-4.

Paul ME, Mitchell CM, Rogers AJ, Fox MC, Lackie EG. Early surgical abortion: efficacy and safety. *Am.J.Obstet.Gynecol.* 2002;**187**:407-11.

Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik F *et al.* Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. *N.Engl.J.Med.* 1993;**328**:1509-13.

- Phelps RH, Schaff EA, Fielding SL. Mifepristone abortion in minors. *Contraception* 2001;**64**:339-43.
- Pongsatha S, Morakot N, Tongsong T. Demographic characteristics of women with self use of misoprostol for pregnancy interruption attending Maharaj Nakorn Chiang Mai Hospital. *J.Med.Assoc.Thai.* 2002;**85**:1074-80.
- Pymar HC, Creinin MD, Schwartz JL. Mifepristone followed on the same day by vaginal misoprostol for early abortion. *Contraception* 2001;**64**:87-92.
- Randel J, French L. Mifepristone and misoprostol for termination of early pregnancy. *J.Fam.Pract.* 1998;**47**:96-7.
- Ravn P, Rasmussen A, Knudsen UB, Kristiansen FV. An outpatient regimen of combined oral mifepristone 400 mg and misoprostol 400 microg for first-trimester legal medical abortion. *Acta Obstet.Gynecol.Scand.* 2005;**84**:1098-102.
- Rorbye C, Norgaard M, Nilas L. Medical versus surgical abortion efficacy, complications and leave of absence compared in a partly randomized study. *Contraception* 2004;**70**:393-9.
- Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. *Contraception* 2004;**70**:313-7.
- Sahu MT, Rajaram S, Saxena AK, Goel N, Ghumman S. Medical termination of pregnancy in acute intermittent porphyria. *Gynecol.Obstet.Invest* 2006;**62**:38-40.
- Salakos N, Kountouris A, Botsis D, Rizos D, Gregoriou O, Detsis G *et al.* First-trimester pregnancy termination with 800 microg of vaginal misoprostol every 12 h. *Eur.J.Contracept.Reprod.Health Care* 2005;**10**:249-54.
- Salomon LJ, Rozenberg P, Szekeres-Bartho J, Malagrida L, Giudicelli Y, Ville Y. Changes in progesterone-induced-blocking-factor expression rates following mifepristone administration in termination of pregnancy at 5 to 8 weeks. *Journal of Maternal-Fetal & Neonatal Medicine* 2005;**17**:353-6.
- Sanchez O, Guerra D. [Moebius syndrome due to the use of misoprostol. Case report]. *Invest Clin.* 2003;**44**:147-53.
- Schaff EA, Eisinger SH, Franks P, Kim SS. Combined methotrexate and misoprostol for early induced abortion. *Arch.Fam.Med.* 1995;**4**:774-9.
- Schaff EA, Wortman M, Eisinger SH, Franks P. Methotrexate and misoprostol when surgical abortion fails. *Obstet.Gynecol.* 1996;**87**:450-2.
- Schaff EA, Eisinger SH, Franks P, Kim SS. Methotrexate and misoprostol for early abortion. *Fam.Med.* 1996;**28**:198-203.

Schaff EA, Penmetsa U, Eisinger SH, Franks P. Methotrexate. A single agent for early abortion. *J.Reprod.Med.* 1997;**42**:56-60.

Schaff EA, Stadalius LS, Eisinger SH, Franks P. Vaginal misoprostol administered at home after mifepristone (RU486) for abortion. *J.Fam.Pract.* 1997;**44**:353-60.

Schaff EA, Penmetsa U, Eisinger SH, Franks P. Methotrexate - A single agent for early abortion. *Journal of Reproductive Medicine* 1997;**42**:56-60.

Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. *Contraception* 1999;**59**:1-6.

Schaff EA, Fielding SL, Eisinger SH, Stadalius LS, Fuller L. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. *Contraception* 2000;**61**:41-6.

Schreiber CA, Creinin MD, Harwood B, Murthy AS. A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. *Contraception* 2005;**71**:447-50.

Shand C, Rose SB, Simmons A, Sparrow MJ. Introduction of early medical abortion in New Zealand: an audit of the first 67 cases. *Aust.N.Z.J.Obstet.Gynaecol.* 2005;**45**:316-20.

Shannon CS, Winikoff B, Hausknecht R, Schaff E, Blumenthal PD, Oyer D *et al.* Multicenter trial of a simplified mifepristone medical abortion regimen. *Obstet.Gynecol.* 2005;**105**:345-51.

Sharma S, El Refaey H, Mitchel H, Ozturk O, Rodeck C. Mifepristone vaginally in an early medical abortion regimen: a pilot study. *Contraception* 2006;**73**:261-4.

Sherris J, Bingham A, Burns MA, Girvin S, Westley E, Gomez PI. Misoprostol use in developing countries: results from a multicountry study. *Int.J.Gynaecol.Obstet.* 2005;**88**:76-81.

Singh K, Fong YF, Dong F. A viable alternative to surgical vacuum aspiration: repeated doses of intravaginal misoprostol over 9 hours for medical termination of pregnancies up to eight weeks. *BJOG.* 2003;**110**:175-80.

Singh KC, Ummat S, Rajaram S, Goel N. First trimester abortion with mifepristone and three doses of sublingual misoprostol: a pilot study. *Aust.N.Z.J.Obstet.Gynaecol.* 2005;**45**:495-8.

Sirimai K, Kiriwat O, Neungton S, Suvanichchati S. Misoprostal use for therapeutic abortion in Siriraj Hospital: the year 2000. *J.Med.Assoc.Thai.* 2002;**85**:416-23.

Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. *N.Engl.J.Med.* 1998;**338**:1241-7.

Stewart P, Fletcher J, Sharma A. Report from the Faculty of Family Planning and Reproductive Health Care AGM, May 2003: Medical termination of pregnancy in the late first trimester. *J.Fam.Plann.Reprod.Health Care* 2003;**29**:243-4.

Suhonen S, Heikinheimo O, Tikka M, Haukkamaa M. The learning curve is rapid in medical termination of pregnancy--first-year results from the Helsinki area. *Contraception* 2003;**67**:223-7.

Svensden PF, Rorbye C, Vejborg T, Nilas L. Comparison of gemeprost and vaginal misoprostol in first trimester mifepristone-induced abortion. *Contraception* 2005;**72**:28-32.

Tang OS, Gao PP, Cheng L, Lee S, Ho PC. Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol. *Contraception* 1998;**57**:89-91.

Tang OS, Wong KS, Tang LC, Ho PC. Pilot study on the use of repeated doses of misoprostol in termination of pregnancy at less than 9 weeks of gestation. *Adv.Contracept.* 1999;**15**:211-6.

Tang OS, Miao BY, Lee SW, Ho PC. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: efficacy and acceptability. *Hum.Reprod.* 2002;**17**:654-8.

Tang OS, Xu J, Cheng L, Lee SW, Ho PC. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. *Hum.Reprod.* 2002;**17**:1738-40.

Thong KJ, Baird DT. Induction of abortion with mifepristone and misoprostol in early pregnancy. *Br.J.Obstet.Gynaecol.* 1992;**99**:1004-7.

Thong KJ, Dewar MH, Baird DT. What do women want during medical abortion? *Contraception* 1992;**46**:435-42.

Todd CS, Soler M, Castleman L, Rogers MK, Blumenthal PD. Buccal misoprostol as cervical preparation for second trimester pregnancy termination. *Contraception* 2002;**65**:415-8.

Tsai EM, Yang CH, Lee JN. Medical abortion with mifepristone and misoprostol: a clinical trial in Taiwanese women. *J.Formos.Med.Assoc.* 2002;**101**:277-82.

Urquhart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, McGarry J *et al.* The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicentre study - Final results. *Contraception* 1997;**55**:1-5.

Velazco A, Varela L, Tanda R, Sanchez C, Barambio S, Chami S *et al.* Misoprostol for abortion up to 9 weeks' gestation in adolescents. *Eur.J.Contracept.Reprod.Health Care* 2000;**5**:227-33.

Weeks AD, Stewart P. The Use of Low-Dose Mifepristone and Vaginal Misoprostol for First Trimester Termination of Pregnancy. *British Journal of Family Planning* 1995;**21**:85-6.

Westhoff C, Dasmahapatra R, Winikoff B, Clarke S. Predictors of analgesia use during supervised medical abortion. The Mifepristone Clinical Trials Group. *Contraception* 2000;**61**:225-9.

Westhoff C, Picardo L, Morrow E. Quality of life following early medical or surgical abortion. *Contraception* 2003;**67**:41-7.

Wheeler M, O'Meara P, Stanford M. Fetal methotrexate and misoprostol exposure: the past revisited. *Teratology* 2002;**66**:73-6.

Wiebe E, Guilbert E, Jacot F, Shannon C, Winikoff B. A fatal case of *Clostridium sordellii* septic shock syndrome associated with medical abortion. *Obstet.Gynecol.* 2004;**104**:1142-4.

Wiebe ER. Abortion induced with methotrexate and misoprostol. *CMAJ.* 1996;**154**:165-70.

Wiebe ER. Choosing between surgical abortions and medical abortions induced with methotrexate and misoprostol. *Contraception* 1997;**55**:67-71.

Wiebe ER. Comparing abortion induced with methotrexate and misoprostol to methotrexate alone. *Contraception* 1999;**59**:7-10.

Wilson T, Thong KJ, Howie PW. Decrease in human plasma gravidin levels after medical abortion. *Prostaglandins* 1994;**48**:175-85.

Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao B, Gu S *et al.* Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. *Am.J.Obstet.Gynecol.* 1997;**176**:431-7.

Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. *Arch.Fam.Med.* 1998;**7**:360-6.

Xiao B, von Hertzen H, Zhao H, Piaggio G. Menstrual induction with mifepristone and misoprostol. *Contraception* 2003;**68**:489-94.

Xu J, Chen H, Ma T, Wu X. Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol. *Int.J.Gynaecol.Obstet.* 2001;**72**:245-51.

Yedlinsky NT, Morgan FC, Whitecar PW. Anomalies associated with failed methotrexate and misoprostol termination. *Obstet.Gynecol.* 2005;**105**:1203-5.

Yip SK, Tse AO, Haines CJ, Chung TK. Misoprostol's effect on uterine arterial blood flow and fetal heart rate in early pregnancy. *Obstet.Gynecol.* 2000;**95**:232-5.

Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. *Obstet.Gynecol.* 1997;**90**:88-92.

Zikopoulos KA, Papanikolaou EG, Kalantaridou SN, Tsanadis GD, Plachouras NI, Dalkalitsis NA *et al.* Early pregnancy termination with vaginal misoprostol before and after 42 days gestation. *Hum.Reprod.* 2002;**17**:3079-83.

Cost-effectiveness

Penney GC, Mckessock L, Rispin R, ElRefaey H, Templeton A. An Effective, Low-Cost Regimen for Early Medical Abortion. *British Journal of Family Planning* 1995;**21**:5-6.

Rocconi RP, Chiang S, Richter HE, Straughn JM. Management strategies for abnormal early pregnancy - A cost-effectiveness analysis. *Journal of Reproductive Medicine* 2005;**50**:486-90.

Pharmacology

Chen Y, Cao L, Gu ZP. [Effect of gossypol in combination with misoprostol on termination of early pregnancy in rats and mice]. *Yao Xue.Xue.Bao.* 1997;**32**:801-7.

Coelho KE, Sarmiento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV *et al.* Misoprostol embryotoxicity: clinical evaluation of fifteen patients with arthrogyposis. *Am.J.Med.Genet.* 2000;**95**:297-301.

Elul B, Ellertson C, Winikoff B, Coyaji K. Side effects of mifepristone-misoprostol abortion versus surgical abortion. Data from a trial in China, Cuba, and India. *Contraception* 1999;**59**:107-14.

Fonseca W, Alencar AJ, Pereira RM, Misago C. Congenital malformation of the scalp and cranium after failed first trimester abortion attempt with misoprostol. *Clin.Dysmorphol.* 1993;**2**:76-80.

Genest DR, Di Salvo D, Rosenblatt MJ, Holmes LB. Terminal transverse limb defects with tethering and omphalocele in a 17 week fetus following first trimester misoprostol exposure. *Clin.Dysmorphol.* 1999;**8**:53-8.

Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. *N.Engl.J.Med.* 2001;**344**:38-47.

Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ *et al.* Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. *Am.J.Med.Genet.* 1993;**47**:59-64.

He QJ, Yang B, Wang WF, Wu HH, Fang RY. Synergistic effects of DL111-IT in combination with mifepristone and misoprostol on termination of early pregnancy in preclinical studies. *Contraception* 2003;**68**:289-95.

Heikinheimo O. Clinical pharmacokinetics of mifepristone. *Clin.Pharmacokinet.* 1997;**33**:7-17.

Koren G.,Schuler L. Taking drugs during pregnancy. How safe are the unsafe? *Can.Fam.Physician* 2001;**47**:951-3.

Nayak NR, Ghosh D, Lasley BL, Sengupta J. Anti-implantation activity of luteal phase mifepristone administration is not mimicked by prostaglandin synthesis inhibitor or prostaglandin analogue in the rhesus monkey. *Contraception* 1997;**55**:103-14.

Nayak NR, Sengupta J, Ghosh D. Antinidatory effect of luteal phase administration of mifepristone (RU486) is associated with changes in endometrial prostaglandins during the implantation window. *Contraception* 1998;**58**:111-7.

Rabe T, Basse H, Thuro H, Kiesel L, Runnebaum B. Action of the Pge1 Methyl Analog Misoprostol on the Pregnant Human-Uterus in the 1St Trimester. *Geburtshilfe und Frauenheilkunde* 1987;**47**:324-31.

Rabe T, Basse H, Thuro H, Kiesel L, Runnebaum B. [Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester]. *Geburtshilfe Frauenheilkd.* 1987;**47**:324-31.

Sanchez O.,Guerra D. [Moebius syndrome due to the use of misoprostol. Case report]. *Invest Clin.* 2003;**44**:147-53.

Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. *Lancet* 1998;**352**:323.

Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. *Contraception* 2006;**74**:48-55.

Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. *Obstet.Gynecol.* 1997;**90**:88-92.

Zust S, Hosli I, Surbek D, Holzgreve W. Side effects of Misoprostol therapy during pregnancy. *Zeitschrift fur Geburtshilfe und Neonatologie* 2001;**205**:43-8.

Zust S, Hosli I, Surbek D, Holzgreve W. [Adverse effects of misoprostol in pregnancy]. *Z.Geburtshilfe Neonatol.* 2001;**205**:43-8.

Politics/ Licensing/ Ethics

Abortion drug is effective and safe, U.S. study says. *Contracept.Technol.Update.* 1998;**19**:87-8.

Abortion drugs must become WHO essential medicines. *Lancet* 2005;**365**:1826.

[Anon]. USFDA, pharmacia new ruling on misoprostol. *Reproductive Health Matters* 2002;**10**:192-3.

Baulieu EE. Updating RU 486 development. *Law Med.Health Care* 1992;**20**:154-6.

Berer M. Medical abortion: a fact sheet. *Reprod.Health Matters.* 2005;**13**:20-4.

Chong YS, Su LL, Arulkumaran S. Misoprostol: a quarter century of use, abuse, and creative misuse. *Obstet.Gynecol.Surv.* 2004;**59**:128-40.

Creinin M, Blumenthal P, Shulman L. Mortality associated with mifepristone-misoprostol medical abortion. *MedGenMed.* 2006;**8**:26.

Ellertson C., Waldman SN. The mifepristone-misoprostol regimen for early medical abortion. *Curr.Womens Health Rep.* 2001;**1**:184-90.

Faucher P, Baunot N, Madelenat P. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. *Gynecol.Obstet.Fertil.* 2005;**33**:220-7.

Gebhardt DO. Misoprostol in a topsyturvy world. *J.Med.Ethics* 2001;**27**:205.

Harper CC, Henderson JT, Darney PD. Abortion in the United States. *Annual Review of Public Health* 2005;**26**:501-12.

Healy DL. Prostaglandins and progesterone receptor antagonists in human fertility regulation. *Aust.N.Z.J.Obstet.Gynaecol.* 1994;**34**:357-60.

Klitsch M. Antiprogestins and the abortion controversy: a progress report. *Fam.Plann.Perspect.* 1991;**23**:275-82.

Lourenco AP, Reuse C, de Ziegler D. [Early pregnancy termination: what the generalist should know]. *Rev.Med.Suisse* 2006;**2**:1340-5.

Murphy F, Jordan S, Jones L. Care of women having termination of first-trimester pregnancy. *Br.J.Nurs.* 2000;**9**:2235-41.

Murthy A, Creinin MD. Pharmacoeconomics of medical abortion: a review of cost in the United States, Europe and Asia. *Expert.Opin.Pharmacother.* 2003;**4**:503-13.

Rosenfield A. Mifepristone (RU 486) in the United States. What does the future hold? *N.Engl.J.Med.* 1993;**328**:1560-1.

Rutter TL. Drug combination adds fuel to US abortion debate. *BMJ* 1995;**311**:705.

Weeks AD, Fiala C, Safar P. Misoprostol and the debate over off-label drug use. *BJOG.* 2005;**112**:269-72.

Unspecified

Mifepristone and misoprostol for early abortion. *JNMA.J.Nepal.Med.Assoc.* 2006;**45**:I.

[Anon]. Self-administration of misoprostol at 10-13 weeks of pregnancy. *Reproductive Health Matters* 2000;**8**:178-9.

Aubeny E, Baulieu EE. [Contraceptive activity of RU486 and oral active prostaglandin combination]. *C.R.Acad.Sci.III* 1991;**312**:539-45.